Alpha 2.0
Login Register
» Authors » N Boeckx

N Boeckx

Explore the profile of N Boeckx including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 530
Followers 0
Related Specialties
Hematology
Oncology
General Medicine
Top 10 Co-Authors
V H J van der Velden
J J M van Dongen
P Vandenberghe
T Szczepanski
P G Hoogeveen
A Orfao
H El Housni
F Nollet
W M Comans-Bitter
S Bottcher
Published In
Leukemia
Int J Lab Hematol
Acta Clin Belg
J Biol Regul Homeost Agents
Blood Cancer J
Affiliations
Soon will be listed here.
Recent Articles
21.
Detection of minimal residual disease in acute leukemia
van der Velden V, Boeckx N, van Wering E, van Dongen J
J Biol Regul Homeost Agents . 2004 Oct; 18(2):146-54. PMID: 15471219
Detection of minimal residual disease (MRD) has prognostic value in acute lymphoblastic leukemia and acute myeloid leukemia. Particularly the evaluation of early treatment response has high prognostic value, because this...
22.
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia
Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, et al.
Nat Genet . 2004 Sep; 36(10):1084-9. PMID: 15361874
In T-cell acute lymphoblastic leukemia (T-ALL), transcription factors are known to be deregulated by chromosomal translocations, but mutations in protein tyrosine kinases have only rarely been identified. Here we describe...
23.
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients
van der Velden V, Boeckx N, Jedema I, Te Marvelde J, Hoogeveen P, Boogaerts M, et al.
Leukemia . 2004 Mar; 18(5):983-8. PMID: 15029214
Gemtuzumab ozogamicin (Mylotarg) induces remission in approximately 30% of relapsed AML patients. We previously demonstrated that gemtuzumab infusion results in near-complete CD33 saturation in peripheral blood, and that saturating gemtuzumab...
24.
Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program
van der Velden V, Boeckx N, Gonzalez M, Malec M, Barbany G, Lion T, et al.
Leukemia . 2004 Feb; 18(4):884-6. PMID: 14961029
No abstract available.
25.
Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation
Vandenberghe P, Boeckx N, Ronsyn E, Decorte R, Verhoef G, Hagemeijer A
Leukemia . 2003 Feb; 17(2):458-60. PMID: 12592347
No abstract available.
26.
Persistent polyclonal B-cell lymphocytosis
Ide L, Dekoninck A, Verburgh E, Goossens W, Brusselmans C, Boeckx N, et al.
Acta Clin Belg . 2002 May; 57(1):31-3. PMID: 12017755
We present a case of persistent polyclonal B-cell lymphocytosis (PPBL). This syndrome is characterized by a persistent lymphocytosis with circulating atypical binucleated lymphocytes. The patient had serological evidence of a...
27.
Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia
Boeckx N, Willemse M, Szczepanski T, van der Velden V, Langerak A, Vandekerckhove P, et al.
Leukemia . 2002 Mar; 16(3):368-75. PMID: 11896540
PCR-based monitoring of minimal residual disease (MRD) in acute leukemias can be achieved via detection of fusion gene transcripts of chromosome aberrations or detection of immunoglobulin (Ig) and T cell...